Q1 2026 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062462
$237.1M
Reported value
8
Positions
2026-03-31
Period end
The Brief · Foresite Capital Management IV, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in Eikon Therapeutics, Inc. EIKN valued at $20.56M. The fund also increased its stake in CYTOKINETICS INC CYTK by 9.82%. Conversely, the fund trimmed its holding in Maze Therapeutics, Inc. MAZE by 69.98%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $135.0M | 56.9% | 4,778,581 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $33.2M | 14.0% | 503,295 | Common | SOLE |
| 282564103 | EIKN | Eikon Therapeutics, Inc. | $20.6M | 8.67% | 1,943,682 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $16.1M | 6.77% | 800,399 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $9.9M | 4.20% | 1,000,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $9.3M | 3.92% | 160,000 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $8.4M | 3.53% | 3,887,200 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $4.7M | 1.98% | 156,901 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.